Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XL784
- Development stage
- Phase 2
- Lead developer
- Exelixis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
XL784 is a potent small molecule inhibitor of the ADAM-10 metalloprotease enzyme, developed by Exelixis. It was designed to selectively inhibit ADAM-10 and matrix metalloproteinase 2 (MMP-2), while sparing MMP-1, which may enhance its safety profile compared to other metalloprotease inhibitors. The drug acts as an angiogenesis inhibitor and has demonstrated efficacy in preclinical models for reducing aortic dilatation and proteinuria. XL784 was investigated primarily for diabetic nephropathies (including albuminuria) and cancer, with clinical trials reaching Phase II before development was discontinued[1][2][4][7].
02
Targets
ADAM10 (Disintegrin and metalloproteinase domain-containing protein 10)ADAM17 (A disintegrin and metalloprotease 17)MMP13 (Matrix metalloproteinase-13)MMP2 (Matrix metalloproteinase-2)MMP9 (Matrix metalloproteinase-9)
Beyond the preview
Go deeper on XL784.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XL784.